Catalyst Pharmaceuticals Stock Price on October 24, 2024
| CPRX Stock | USD 22.11 0.37 1.70% |
Below is the normalized historical share price chart for Catalyst Pharmaceuticals extending back to November 08, 2006. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Catalyst Pharmaceuticals stands at 22.11, as last reported on the 11th of December 2024, with the highest price reaching 22.14 and the lowest price hitting 21.70 during the day.
If you're considering investing in Catalyst Stock, it is important to understand the factors that can impact its price. At this stage we consider Catalyst Stock to be very steady. Catalyst Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0743, which signifies that the company had a 0.0743% return per unit of risk over the last 3 months. We have found thirty technical indicators for Catalyst Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please confirm Catalyst Pharmaceuticals' Downside Deviation of 1.92, mean deviation of 1.57, and Risk Adjusted Performance of 0.0791 to double-check if the risk estimate we provide is consistent with the expected return of 0.14%.
At this time, Catalyst Pharmaceuticals' Total Stockholder Equity is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 493.6 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 57 M in 2024. . At this time, Catalyst Pharmaceuticals' Price Earnings Ratio is fairly stable compared to the past year. Price To Operating Cash Flows Ratio is likely to rise to 13.06 in 2024, whereas Price To Sales Ratio is likely to drop 4.26 in 2024. Catalyst Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 8th of November 2006 | 200 Day MA 18.0574 | 50 Day MA 21.4778 | Beta 0.755 |
Catalyst |
Sharpe Ratio = 0.0743
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | CPRX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.92 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Catalyst Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Catalyst Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 3.99 | Enterprise Value Ebitda 10.3962 | Price Sales 5.6906 | Shares Float 103 M | Wall Street Target Price 32.25 |
Related Headline
Inozyme Pharma Headline on 24th of October 2024
Inozyme Pharma Announces Positive Interim Data from Phase 1 ... by finance.yahoo.com
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate levels in patients with end-stage kidney disease undergoing hemodialysis low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD - - Company plans to initiate a registrational trial in calciphylaxis in 2025 subject to regulatory alignment and sufficient funding - BOSTON, Oct. 24, 2024 -- Inozyme Pharma, Inc. the Company or Inozyme
Catalyst Pharmaceuticals Valuation on October 24, 2024
It is possible to determine the worth of Catalyst Pharmaceuticals on a given historical date. On October 24, 2024 Catalyst was worth 21.37 at the beginning of the trading date compared to the closed value of 21.41. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Catalyst Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Catalyst Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Catalyst Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Catalyst Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 21.46 | 21.62 | 21.02 | 21.34 | 583,234 | |
10/24/2024 | 21.37 | 21.62 | 21.11 | 21.41 | 526,504 |
| 21.50 | 21.93 | 21.42 | 21.46 | 550,474 |
| Backtest Catalyst Pharmaceuticals | | | Catalyst Pharmaceuticals History | | | Catalyst Pharmaceuticals Valuation | Previous | Next |
Catalyst Pharmaceuticals Trading Date Momentum on October 24, 2024
| On October 25 2024 Catalyst Pharmaceuticals was traded for 21.46 at the closing time. The top price for the day was 21.93 and the lowest listed price was 21.42 . The trading volume for the day was 550.5 K. The trading history from October 25, 2024 was a factor to the next trading day price jump. The overall trading delta against the next closing price was 0.23% . The overall trading delta against the current closing price is 1.91% . |
Catalyst Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Catalyst Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Catalyst financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Catalyst Pharmaceuticals Stock history
Catalyst Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Catalyst is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Catalyst Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Catalyst Pharmaceuticals stock prices may prove useful in developing a viable investing in Catalyst Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 113.8 M | 57 M | |
| Net Income Applicable To Common Shares | 95.5 M | 100.3 M |
Catalyst Pharmaceuticals Quarterly Net Working Capital |
|
Catalyst Pharmaceuticals Stock Technical Analysis
Catalyst Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Catalyst Pharmaceuticals Period Price Range
Low | December 11, 2024
| High |
0.00 | 0.00 |
Catalyst Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Catalyst Pharmaceuticals December 11, 2024 Market Strength
Market strength indicators help investors to evaluate how Catalyst Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Catalyst Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Catalyst Pharmaceuticals stock market strength indicators, traders can identify Catalyst Pharmaceuticals entry and exit signals to maximize returns
Catalyst Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Catalyst Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Catalyst Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Catalyst to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0791 | |||
| Jensen Alpha | 0.159 | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | 0.0382 | |||
| Treynor Ratio | 0.7433 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.